title: Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients.
abstract: The study was undertaken to evaluate macrophage-derived chemokine (CCL22) levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n = 93) in relation to regulatory T cells (Tregs; n = 75). The peritoneal fluid CCL22 concentrations were significantly higher in epithelial ovarian cancer (EOC) patients than in patients with benign tumors-serous cystadenoma (n = 32). There was no difference in plasma levels of CCL22 in EOC patients compared with the non-cancer and healthy volunteers (n = 10). There were no significant differences in the plasma and PF CCL22 levels based on tumor grade. However, women with stage IV FIGO (International Federation of Gynecologists and Obstetricians) had significantly higher plasma CCL22 levels than patients with stages I and III. Women with stage I FIGO had significantly higher PF CCL22 levels than patients with stages II and III. Women with endometrioid cystadenocarcinoma had higher PF CCL22 levels than women with undifferentiated carcinoma. The percentage of tumor-infiltrating Tregs (11.06 %) was significantly higher compared to PF (3.05 %) and peripheral blood (PB) (2.01 %). Moreover, the percentage of Tregs was higher in the PF than in the PB of EOC patients. There were no significant differences in the PB, PF, and tumor-infiltrating Tregs percentage based on tumor stage, grade, or histology. Elevated levels of CCL22 found in the ascites could create a chemokine gradient aiding in Treg cells migration. Increased Tregs percentage in the local microenvironment of ovarian cancer might be an important mechanism of immunosuppression.
authors: I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16, 20-081, Lublin, Poland, iwonawertel@wp.pl.
authors: I
authors: I
authors: Wertel
authors: J
authors: J
authors: Surówka
authors: G
authors: G
authors: Polak
authors: B
authors: B
authors: Barczyński
authors: W
authors: W
authors: Bednarek
authors: J
authors: J
authors: Jakubowicz-Gil
authors: A
authors: A
authors: Bojarska-Junak
authors: J
authors: J
authors: Kotarski
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001202:Ascitic Fluid / Q000378:metabolism / Q000473:pathology; D054422:Chemokine CCL22 / Q000096:biosynthesis* / Q000235:genetics; D003713:Dendritic Cells / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000473:pathology*; D008264:Macrophages / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000473:pathology*
chemical_list: C515482:CCL22 protein, human; D054422:Chemokine CCL22
references: J Immunol. 2013 Sep 1;191(5):2266-72
references: 23878314
references: PLoS One. 2013;8(10):e76379
references: 24124553
references: Blood. 2011 Nov 3;118(18):4853-62
references: 21908423
references: Cancer Res. 2011 Oct 1;71(19):6143-52
references: 21852386
references: Int Rev Immunol. 2011 Apr-Jun;30(2-3):87-101
references: 21557636
references: Dis Esophagus. 2010 Jul;23(5):422-9
references: 20002703
references: PLoS One. 2009;4(7):e6412
references: 19641607
references: Cancer Res. 2009 May 1;69(9):3995-4000
references: 19383912
references: Cancer Res. 2009 Mar 1;69(5):2000-9
references: 19244125
references: Cancer Immunol Immunother. 2009 Mar;58(3):449-59
references: 18791714
references: Pediatr Allergy Immunol. 2008 Nov;19(7):605-13
references: 18266834
references: Cytometry B Clin Cytom. 2008 Jul;74(4):251-8
references: 18302193
references: Int J Cancer. 2008 May 15;122(10):2286-93
references: 18224687
references: Br J Haematol. 2008 Mar;140(5):527-36
references: 18275430
references: Clin Immunol. 2007 Dec;125(3):291-8
references: 17911044
references: Cancer Lett. 2007 Aug 8;253(1):144-53
references: 17353088
references: J Immunol. 2007 Mar 1;178(5):2883-92
references: 17312132
references: J Immunol. 2006 Nov 15;177(10):7398-405
references: 17082659
references: J Immunother. 2014 Apr;37(3):163-9
references: 24598451
references: Int J Gynecol Pathol. 2000 Jan;19(1):7-15
references: 10638449
references: J Leukoc Biol. 2000 Sep;68(3):400-4
references: 10985257
references: Cancer Res. 2001 Jun 15;61(12):4766-72
references: 11406550
references: J Exp Med. 2001 Sep 17;194(6):847-53
references: 11560999
references: Nat Med. 2004 Sep;10(9):942-9
references: 15322536
references: J Exp Med. 1997 May 5;185(9):1595-604
references: 9151897
references: Blood. 1999 Sep 15;94(6):1890-8
references: 10477717
references: Cancer Invest. 2005;23(5):399-403
references: 16193639
references: Clin Cancer Res. 2005 Dec 1;11(23):8326-31
references: 16322292
references: J Immunol. 2006 Jul 1;177(1):84-91
references: 16785502
references: J Dermatol Sci. 2006 Nov;44(2):93-9
references: 17008059
references: Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
references: 24219974
references: Cancer Cell. 2012 Sep 11;22(3):291-303
references: 22975373